-26.7% · 90d
$1.84
+0.09 (+5.14%)
After-Hours $1.84(+0.00)
News
(1)April 2026
Coherus (CHRS) advances oncology focus, requests option repricing and shares
CHRSCoherus Oncology, Inc.
# 📜 What This Document Is 🗓️ This document is a Definitive Proxy Statement (DEF 14A). Think of it as an annual report card for shareholders, telling you everything the company needs you to know before you vote at the upcoming Annual Meeting. It isn't a financial report itself, but rather a guide t
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%